In: Columbus Venture Partners

  1. Home
  2. News
Caixa Capital Risc
27/06/2019
Caixa Capital Risc   Caixa Capital Risc leads the largest operation in the history of the biotechnology sector in Spain https://www.abc.es/economia/abci-criteriacaixa-capital-lidera-mayor-operacion-historia-sector-biotecnologico-espana-201906260918_noticia.html Read More
AskBio Partners with TPG and Vida Ventures
12/04/2019
AskBio Partners with TPG and Vida Ventures   Leading gene therapy company announces $235 million investment to accelerate growth https://www.businesswire.com/news/home/20190411005352/en/AskBio-Partners-TPG-Vida-Ventures Read More
Aura Biosciences Completes $40 Million Series D Financing
02/04/2019
Aura announces the $40 million Series D round April 02, 2019.CAMBRIDGE, Mass.-Aura Biosciences, a leader in the development of novel targeted... Read More
Pfizer secures exclusive option to acquire Vivet Therapeutics
20/03/2019
Pfizer acquires 15% ownership stake in Vivet   Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),... Read More
PTS opens the first plant in Europe to manufacture polipeptides
20/03/2019

Industrial scale of nanomedicine….

Read More
Columbus register at the CNMV its second Fund , Columbus Life Science Fund II
04/02/2019
Columbus Life Science Fund II will complete the first closing by end of February with a target of €70M   MADRID... Read More
Columbus launches its second Fund; €70M for Biomedicine
24/01/2019
The venture capital firm has its second fund ready to invest in health sciencie companies     Valencia, Spain, January 2019-... Read More
Viralgen Vector Core will be the Gene Therapy reference in Spain
18/09/2018
The president of the Basque Government, Iñigo Urkullu, has chaired the inauguration ceremony of Viralgen Vector Core, the first plant of... Read More
Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting
26/07/2018
  Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy
20/06/2018
  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More